Sai-Hong Ignatius Ou

Professor Sai-Hong Ignatius Ou is currently the Health Science Clinical Professor of Medicine in the Department of Medicine, Division of Hematology-Oncology at the University of California Irvine School of Medicine. Dr. Ou received his MD and PhD degrees from the University of Texas Southwestern Medical School and completed an internship and residency in internal medicine at Duke University Medical Center. Dr. Ou completed his hematology-oncology fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School. Dr. Ou has served as an institutional review committee member for more than 10 years at the University of California Irvine School of Medicine and has been involved in mentoring hematology-oncology fellows and other young investigators globally.

Dr. Ou is one of the eight original phases 1 investigators of crizotinib, and is the senior and corresponding author of the US phase 1 dose escalation of alectinib in the US and participated in the clinical trials of lorlatinib. Dr. Ou has published close to 130 peer-reviewed articles including publications in the New England Journal of Medicine, The Lancet Oncology, Journal of Clinical Oncology, JAMA Oncology, and Cancer Discovery. Dr. Ou was on the scientific advisory board of TurningPoint Therapeutics which is developing the fourth-generation ALK/ROS1/NTRK inhibitor that can overcome solvent front mutations. His major research interests are in targeted therapy in lung cancer and other solid malignancies that harbors actionable driver mutations in particular receptor tyrosine kinase fusions and the strategies to overcome resistance to tyrosine kinase inhibitors. Dr. Ou serves on the editorial board of Annals of Oncology, Clinical Lung Cancer, and Translational Lung Cancer Research and has been an ad hoc reviewer for the New England Journal of Medicine, The Lancet, The Lancet Oncology, and Journal of Clinical Oncology among other journals. Dr. Ou is on the scientific committee for metastatic lung cancer at the American Society of Clinical Oncology annual meeting from 2016-2018.